Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of 8-Oh-Dpat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A known ✓ | P08908 | 6/20 | 0.97 |
| ▸ | HTR1D known ✓ | P28221 | 2/20 | 0.97 |
| ▸ | HTR1B known ✓ | P28222 | 1/20 | 0.97 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.97 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.97 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.78 |
| ▸ | BLM | P54132 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | DRD2 | P14416 | 5/20 | 0.97 |
| ▸ | DRD3 | P35462 | 5/20 | 0.97 |
| ▸ | HTR7 | P34969 | 4/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.97 |
| ▸ | TSHR | P16473 | 1/20 | 0.97 |
| ▸ | HTR2A | P28223 | 1/20 | 0.97 |
| ▸ | HTR2C | P28335 | 1/20 | 0.97 |
| ▸ | HTR2B | P41595 | 1/20 | 0.97 |
| ▸ | HTR5A | P47898 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 8-Oh-Dpat SCHEMBL1682320 | 1.00 | BLM (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| 8-Oh-Dpat SCHEMBL1682286 | 1.00 | BLM (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| 8-Oh-Dpat SCHEMBL496783 | 0.99 | HTR1A (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| 8-Oh-Dpat SCHEMBL29565039 | 0.99 | HTR1A (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| 8-Oh-Dpat SCHEMBL1682330 | 0.99 | HTR1A (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| 8-Oh-Dpat SCHEMBL1682347 | 0.99 | HTR1A (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| 8-Oh-Dpat SCHEMBL29389900 | 0.99 | HTR1A (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| SCHEMBL8892193 | 0.93 | HTR1A (1.00) | BLMALDH1A1LMNAPMP22HTR1A | |
| SCHEMBL8891873 | 0.93 | HTR1A (0.90) | BLMALDH1A1LMNAPMP22HTR1A | |
| 8-Oh-Dpat SCHEMBL29420387 | 0.89 | HTR1A (0.82) | BLMALDH1A1LMNAPMP22HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3231446-B1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2026-01-07 | — | — | EP | disclosed |
| EP-2911695-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PARKINSON DISEASE BY THE SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | PALOMO LTD (CY) | 2023-11-29 | — | — | EP | disclosed |
| US-10646457-B2 | Emesis treatment | REPURPOSED THERAPEUTICS, INC (US) | 2020-05-12 | — | — | US | disclosed |
| US-20190231714-A1 | EMESIS TREATMENT | REPURPOSED THERAPEUTICS, INC | 2019-08-01 | — | — | US | disclosed |
| US-10206889-B2 | Emesis treatment | REPURPOSED THERAPEUTICS, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10125363-B2 | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2018-11-13 | — | — | US | disclosed |
| US-10071163-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20180161287-A1 | EMESIS TREATMENT | EPIOMED THERAPEUTICS, INC. | 2018-06-14 | — | — | US | disclosed |
| US-9918949-B2 | Emesis treatment | REPURPOSED THERAPEUTICS, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| EP-3231446-A1 | COMPOSITIONS AND METHODS FOR SELECTIVE DELIVERY OF OLIGONUCLEOTIDE MOLECULES TO SPECIFIC NEURON TYPES | Nlife Therapeutics S.L. (ES) | 2017-10-18 | — | — | EP | disclosed |
| US-9084825-B2 | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2015-07-21 | — | — | US | disclosed |
| US-20150005388-A1 | EMESIS TREATMENT | EPIOMED THERAPEUTICS, INC. | 2015-01-01 | — | — | US | disclosed |
| US-20140120158-A1 | Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types | PALOMO LIMITED (CY) | 2014-05-01 | — | — | US | disclosed |
| US-8637263-B1 | Assay for determination of compounds having anti-emetic activity | EPIOMED THERAPEUTICS, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | NLIFE THERAPEUTICS, S.L. (ES) | 2012-12-20 | — | — | US | disclosed |
| EP-2488171-A2 | EMESIS TREATMENT | Epiomed Therapeutics, Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120208892-A1 | EMESIS TREATMENT | EPIOMED THERAPEUTICS, INC. (US) | 2012-08-16 | — | — | US | disclosed |
| EP-2380595-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | Nlife Therapeutics S.L. (ES) | 2011-10-26 | — | — | EP | disclosed |
| US-8041258-B2 | Process cartridge and image forming apparatus | BROTHER KOGYO KABUSHIKI KAISHA (JP) | 2011-10-18 | — | — | US | disclosed |
| WO-2011047350-A2 | EMESIS TREATMENT | HELTON DAVID (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10206889-B2 | Emesis treatment | SLC10A2, TTR, NTSR2 | HTR1A 146/4885HTR1D 170/4885HTR1B 85/4885 |
| US-10071163-B2 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | SLC6A2, SLC18A2, SLC1A1 | HTR1A 1481/4885HTR1D 3095/4885HTR1B 1214/4885 |
| US-20120208892-A1 | EMESIS TREATMENT | NTSR2, AVPR2, SLC10A2 | HTR1A 428/4885HTR1D 312/4885HTR1B 126/4885 |
| US-10646457-B2 | Emesis treatment | SLC10A2, TTR, NTSR2 | HTR1A 146/4885HTR1D 170/4885HTR1B 85/4885 |
| US-20150005388-A1 | EMESIS TREATMENT | NTSR2, AVPR2, SLC10A2 | HTR1A 428/4885HTR1D 312/4885HTR1B 126/4885 |
| US-20180161287-A1 | EMESIS TREATMENT | SLC10A2, TTR, NTSR2 | HTR1A 146/4885HTR1D 170/4885HTR1B 85/4885 |
| US-20140120158-A1 | Compositions and Methods for the Treatment of Parkinson Disease by the Selective Delivery of Oligonucleotide Molecules to Specific Neuron Types | SLC6A2, SLC6A3, SLC6A4 | HTR1A 175/4885HTR1D 690/4885HTR1B 197/4885 |
| US-20190231714-A1 | EMESIS TREATMENT | SLC10A2, TTR, NTSR2 | HTR1A 146/4885HTR1D 170/4885HTR1B 85/4885 |
| US-10125363-B2 | Compositions and methods for the treatment of parkinson disease by the selective delivery of oligonucleotide molecules to specific neuron types | SLC6A2, SLC6A3, SLC6A4 | HTR1A 175/4885HTR1D 690/4885HTR1B 197/4885 |
| US-20120322991-A1 | Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types | SLC6A2, SLC18A2, SLC1A1 | HTR1A 1481/4885HTR1D 3095/4885HTR1B 1214/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.